Table S1: Relative risks for hospitalised virologically-confirmed dengue cases due to any serotype of any severity by age group 2-5 years and 6-8 years in CYD14 and 4-5 years and 6-8 in 2-8 years in CYD23/57.
Age group / Time period / CYD-TDV vaccine group / Control group / Relative risk (95% CI)(N=23,429) / (N=11,694)
Cases / M / Annual incidence rate % (95% CI) / Cases1 / M / Annual incidence rate % (95% CI)
CYD14
2-5 years / Year 1 / 8 / 1,656 / 0.5 (0.2; 0.9) / 6 / 825 / 0.7 (0.3; 1.6) / 0.664 / (0.20; 2.32)
Year 2 / 9 / 1,642 / 0.5 (0.2; 1.0) / 7 / 818 / 0.8 (0.3; 1.6) / 0.641 / (0.21; 2.02)
Years 1& 2 / 17 / 1,649 / 0.5 (0.3; 0.8) / 13 / 822 / 0.8 (0.4; 1.3) / 0.651 / (0.30; 1.46)
Year 3 / 15 / 1,636 / 1.0 (0.6; 1.6) / 1 / 813 / 0.1 (0.0; 0.7) / 7.454 / (1.15; 313.80)
Year 4 / 20 / 1,627 / 1.2 (0.8; 1.9) / 7 / 811 / 0.9 (0.3; 1.8) / 1.424 / (0.58; 3.99)
Years 3 & 4 / 35 / 1,632 / 1.1 (0.8; 1.6) / 8 / 812 / 0.5 (0.2; 1.0) / 2.177 / (0.99; 5.43)
Years 1 to 4 / 52 / 1,640 / 0.8 (0.6; 1.0) / 21 / 817 / 0.6 (0.4; 1.0) / 1.233 / (0.73; 2.16)
6-8 years / Year 1 / 5 / 1,877 / 0.3 (0.1; 0.6) / 12 / 942 / 1.3 (0.7; 2.2) / 0.209 / (0.06 0.64)
Year 2 / 8 / 1,866 / 0.4 (0.2; 0.8) / 9 / 936 / 0.9 (0.4; 1.7) / 0.446 / (0.15; 1.30)
Years 1& 2 / 13 / 1,872 / 0.3 (0.2; 0.6) / 21 / 939 / 1.1 (0.7; 1.6) / 0.311 / (0.14; 0.65)
Year 3 / 4 / 1,857 / 0.2 (0.1; 0.6) / 5 / 928 / 0.6 (0.2; 1.4) / 0.400 / (0.08; 1.86)
Year 4 / 18 / 1,852 / 1.0 (0.6; 1.5) / 9 / 926 / 1.0 (0.4; 1.8) / 1.000 / (0.43; 2.53)
Years 3 & 4 / 22 / 1,855 / 0.6 (0.4; 0.9) / 14 / 927 / 0.8 (0.4; 1.3) / 0.786 / (0.38; 1.66)
Years 1 to 4 / 35 / 1,863 / 0.5 (0.3; 0.7) / 34 / 933 / 0.9 (0.6; 1.3) / 0.516 / (0.31; 0.85)
CYD23/57
4-5 years / Year 1 / 1 / 482 / 0.2 (0.0; 1.2) / 2 / 230 / 0.9 (0.1; 3.1) / 0.239 / (0.00; 4.58)
Year 2 / 3 / 465 / 0.6 (0.1; 1.7) / 1 / 219 / 0.4 (0.0; 2.3) / 1.413 / (0.11; 74.17)
Years 1& 2 / 4 / 474 / 0.4 (0.1; 1.0) / 3 / 225 / 0.6 (0.1; 1.9) / 0.632 / (0.11; 4.32)
Year 3 / 5 / 393 / 1.4 (0.5; 3.2) / 1 / 192 / 0.6 (0.0; 3.1) / 2.443 / (0.27; 115.54)
Year 4 / 5 / 393 / 1.3 (0.4; 2.9) / 3 / 192 / 1.6 (0.3; 4.5) / 0.814 / (0.16; 5.24)
Years 3 & 4 / 10 / 393 / 1.3 (0.6; 2.4) / 4 / 192 / 1.1 (0.3; 2.8) / 1.221 / (0.35; 5.34)
Years 1 to 4 / 14 / 433 / 0.8 (0.4; 1.4) / 7 / 208 / 0.8 (0.3; 1.7) / 0.961 / (0.36; 2.81)
6-8 years / Year 1 / 4 / 1,152 / 0.3 (0.1; 0.9) / 3 / 579 / 0.5 (0.1; 1.5) / 0.670 / (0.11; 4.57)
Year 2 / 18 / 1,107 / 1.5 (0.9; 2.4) / 13 / 564 / 2.1 (1.1; 3.6) / 0.705 / (0.33; 1.57)
Years 1& 2 / 22 / 1,130 / 0.9 (0.6; 1.4) / 16 / 572 / 1.3 (0.8; 2.2) / 0.696 / (0.35; 1.42)
Year 3 / 14 / 945 / 1.6 (0.9; 2.7) / 5 / 473 / 1.2 (0.4; 2.7) / 1.401 / (0.48; 4.97)
Year 4 / 8 / 945 / 0.8 (0.4; 1.7) / 9 / 473 / 1.9 (0.9; 3.6) / 0.445 / (0.15; 1.30)
Years 3 & 4 / 22 / 945 / 1.2 (0.8; 1.8) / 14 / 473 / 1.5 (0.8; 2.6) / 0.787 / (0.38; 1.66)
Years 1 to 4 / 44 / 1,037 / 1.1 (0.8; 1.4) / 30 / 522 / 1.4 (1.0; 2.0) / 0.738 / (0.45; 1.22)
N: number of participants in the safety population, i.e. all participants who received ≥1 dose of either CYD-TDV vaccine or placebo, analysed in the group according to the first injection received; M: number of participants present at the beginning of each year or mean of number of subjects followed during the years included in the considered period; Cases: number of participants with at least one virologically-confirmed dengue episode (two participants had two episodes, but only the first episode was included in this analysis of cases); Annual incidence rate: Cases among M * 100 converted into the annual rate.
Table S2: Relative risks for clinically severe1 hospitalised virologically-confirmed dengue2 due to any serotype in CYD14 and CYD23/57 from Year 1 to Year 4, by age group 2-5 years old and 6-8 years old.
CYD-TDV group / Control group(N=23429) / (N=11694)
Annual incidence rate % / Annual incidence rate % / Relative risk
Study / Study period / Cases / M / (95% CI) / Cases / M / (95% CI) / (95% CI)
2 to 5 years old
CYD14 / Year 1 / 4 / 1,656 / 0.2 (0.1; 0.6) / 1 / 825 / 0.1 (0.0; 0.7) / 1.993 / (0.20; 98.14)
Year 2 / 3 / 1,642 / 0.2 (0.0; 0.5) / 4 / 818 / 0.5 (0.1; 1.2) / 0.374 / (0.05; 2.21)
Years 1& 2 / 7 / 1,649 / 0.2 (0.1; 0.4) / 5 / 822 / 0.3 (0.1; 0.7) / 0.697 / (0.19; 2.79)
Year 3 / 6 / 1,636 / 0.4 (0.1; 0.9) / 0 / 813 / 0.0 (0.0; 0.5) / NC / (NC)
Year 4 / 4 / 1,627 / 0.2 (0.1; 0.6) / 0 / 811 / 0.0 (0.0; 0.5) / NC / (NC)
Years 3 & 4 / 10 / 1,632 / 0.3 (0.2; 0.6) / 0 / 812 / 0.0 (0.0; 0.2) / NC / (NC)
Years 1 to 4 / 17 / 1,640 / 0.3 (0.2; 0.4) / 5 / 817 / 0.2 (0.0; 0.4) / 1.693 / (0.60; 5.87)
CYD23/57 / Year 1 / 0 / 482 / 0.0 (0.0; 0.8) / 0 / 230 / 0.0 (0.0; 1.6) / NC / (NC)
Year 2 / 0 / 465 / 0.0 (0.0; 0.7) / 0 / 219 / 0.0 (0.0; 1.5) / NC / (NC)
Years 1& 2 / 0 / 474 / 0.0 (0.0; 0.4) / 0 / 225 / 0.0 (0.0; 0.8) / NC / (NC)
Year 3 / 2 / 393 / 0.6 (0.1; 2.0) / 0 / 192 / 0.0 (0.0; 2.1) / NC / (NC)
Year 4 / 1 / 393 / 0.3 (0.0; 1.4) / 1 / 192 / 0.5 (0.0; 2.9) / 0.489 / (0.01; 38.35)
Years 3 & 4 / 3 / 393 / 0.4 (0.1; 1.2) / 1 / 192 / 0.3 (0.0; 1.5) / 1.466 / (0.12; 76.94)
Years 1 to 4 / 3 / 433 / 0.2 (0.0; 0.5) / 1 / 208 / 0.1 (0.0; 0.7) / 1.442 / (0.12; 75.70)
CYD14 + CYD23/57 / Year 1 / 4 / 2,138 / 0.2 (0.1; 0.5) / 1 / 1,055 / <0.1 (0.0; 0.5) / 1.974 / (0.20; 97.21)
Year 2 / 3 / 2,107 / 0.1 (0.0; 0.4) / 4 / 1,037 / 0.4 (0.1; 0.9) / 0.369 / (0.05; 2.18)
Years 1& 2 / 7 / 2,123 / 0.2 (0.1; 0.3) / 5 / 1,046 / 0.2 (0.1; 0.5) / 0.690 / (0.19; 2.76)
Year 3 / 8 / 2,029 / 0.4 (0.2; 0.8) / 0 / 1,005 / 0.0 (0.0; 0.4) / NC / (NC)
Year 4 / 5 / 2,020 / 0.2 (0.1; 0.6) / 1 / 1,003 / <0.1 (0.0; 0.6) / 2.483 / (0.28; 117.42)
Years 3 & 4 / 13 / 2,025 / 0.3 (0.2; 0.6) / 1 / 1,004 / <0.1 (0.0; 0.3) / 6.447 / (0.97; 273.98)
Years 1 to 4 / 20 / 2,074 / 0.2 (0.1; 0.4) / 6 / 1,025 / 0.1 (0.1; 0.3) / 1.648 / (0.64; 5.01)
6 to 8 years old
CYD14 / Year 1 / 1 / 1,877 / <0.1 (0.0; 0.3) / 3 / 942 / 0.3 (0.1; 0.9) / 0.167 / (0.00; 2.08)
Year 2 / 2 / 1,866 / <0.1 (0.0; 0.4) / 1 / 936 / <0.1 (0.0; 0.5) / 1.003 / (0.05; 59.19)
Years 1& 2 / 3 / 1,872 / <0.1 (0.0; 0.2) / 4 / 939 / 0.2 (0.1; 0.5) / 0.376 / (0.06; 2.22)
Year 3 / 2 / 1,857 / 0.1 (0.0; 0.4) / 0 / 928 / 0.0 (0.0; 0.4) / NC / (NC)
Year 4 / 5 / 1,852 / 0.3 (0.1; 0.6) / 4 / 926 / 0.4 (0.1; 1.1) / 0.625 / (0.13; 3.15)
Years 3 & 4 / 7 / 1,855 / 0.2 (0.1; 0.4) / 4 / 927 / 0.2 (0.1; 0.6) / 0.875 / (0.22; 4.07)
Years 1 to 4 / 10 / 1,863 / 0.1 (0.1; 0.2) / 8 / 933 / 0.2 (0.1; 0.4) / 0.626 / (0.22; 1.83)
CYD23/57 / Year 1 / 0 / 1,152 / 0.0 (0.0; 0.3) / 0 / 579 / 0.0 (0.0; 0.6) / NC / (NC)
Year 2 / 1 / 1,107 / <0.1 (0.0; 0.5) / 1 / 564 / 0.2 (0.0; 0.9) / 0.509 / (0.01; 39.99)
Years 1& 2 / 1 / 1,130 / <0.1 (0.0; 0.2) / 1 / 572 / <0.1 (0.0; 0.5) / 0.506 / (0.01; 39.72)
Year 3 / 2 / 945 / 0.2 (0.0; 0.8) / 0 / 473 / 0.0 (0.0; 0.8) / NC / (NC)
Year 4 / 0 / 945 / 0.0 (0.0; 0.4) / 1 / 473 / 0.2 (0.0; 1.2) / 0 / (0.00; 19.52)
Years 3 & 4 / 2 / 945 / 0.1 (0.0; 0.4) / 1 / 473 / 0.1 (0.0; 0.6) / 1.001 / (0.05; 59.06)
Years 1 to 4 / 3 / 1,037 / <0.1 (0.0; 0.2) / 2 / 522 / <0.1 (0.0; 0.3) / 0.755 / (0.09; 9.04)
CYD14 + CYD23/57 / Year 1 / 1 / 3,029 / <0.1 (0.0; 0.2) / 3 / 1,521 / 0.2 (0.0; 0.6) / 0.167 / (0.00; 2.08)
Year 2 / 3 / 2,973 / <0.1 (0.0; 0.3) / 2 / 1,500 / 0.1 (0.0; 0.4) / 0.757 / (0.09; 9.06)
Years 1& 2 / 4 / 3,001 / <0.1 (0.0; 0.2) / 5 / 1,511 / 0.2 (0.1; 0.4) / 0.403 / (0.08; 1.87)
Year 3 / 4 / 2,802 / 0.2 (0.0; 0.4) / 0 / 1,401 / 0.0 (0.0; 0.3) / NC / (NC)
Year 4 / 5 / 2,797 / 0.2 (0.1; 0.4) / 5 / 1,399 / 0.4 (0.1; 0.8) / 0.500 / (0.12; 2.17)
Years 3 & 4 / 9 / 2,800 / 0.2 (0.1; 0.3) / 5 / 1,400 / 0.2 (0.1; 0.4) / 0.900 / (0.27; 3.42)
Years 1 to 4 / 13 / 2,900 / 0.1 (0.1; 0.2) / 10 / 1,455 / 0.2 (0.1; 0.3) / 0.652 / (0.26; 1.66)
M: number of participants present at the beginning of each year or mean of number of subjects followed during the years included in the considered period; Cases: number of participants with at least one hospitalisation for virologically-confirmed dengue episode meeting the Independent Data Monitoring Committee criteria; NC: Not calculated; The annual incidence rate: cases among M * 100 converted into the annual rate.1Severity was assessed using the Independent Data Monitoring Committee (IDMC) criteria.
Two VCD cases, judged to be clinically-severe, were not hospitalised: one in the CYD14 control group and one in the CYD15 CYD-TDV group were not included in the analysis.
Table S3:Annual incidence rates and relative risks for participants with clinically-severe1 hospitalised virologically-confirmed dengue, due to any serotype, and by serotype in CYD14, CYD15 and CYD23/57 and combined.
CYD Dengue Vaccine Group / Control Group(N=23,429) / (N=11,694)
Serotype / Time period / Cases / M / Annual incidence rate %
(95% CI) / Cases / M / Annual incidence rate
%(95% CI) / Relative risk (95% CI)
CYD14
Any serotypes / Year 1 / 7 / 6,848 / 0.1 (0.0; 0.2) / 7 / 3,424 / 0.2 (0.1; 0.4) / 0.500 / (0.15; 1.67)
Year 2 / 5 / 6,812 / <0.1 (0.0; 0.2) / 13 / 3,407 / 0.4 (0.2; 0.6) / 0.192 / (0.05; 0.57)
Years 1 & 2 / 12 / 6,830 / <0.1 (0.0; 0.1) / 20 / 3,416 / 0.3 (0.2; 0.4) / 0.300 / (0.13; 0.64)
Year 3 / 11 / 6,778 / 0.2 (0.1; 0.3) / 1 / 3,387 / <0.1 (0.0; 0.2) / 5.497 / (0.80; 236.60)
Year 4 / 13 / 6,755 / 0.2 (0.1; 0.3) / 6 / 3,376 / 0.2 (0.1; 0.4) / 1.083 / (0.38; 3.47)
Years 3 & 4 / 24 / 6,767 / 0.2 (0.1; 0.3) / 7 / 3,382 / 0.1 (0.0; 0.2) / 1.713 / (0.72; 4.71)
Years 1 to 4 / 36 / 6,798 / 0.1 (0.1; 0.2) / 27 / 3,399 / 0.2 (0.1; 0.3) / 0.667 / (0.39; 1.14)
Serotype 1 / Year 1 / 3 / 6,848 / <0.1 (0.0; 0.1) / 3 / 3,424 / <0.1 (0.0; 0.3) / 0.500 / (0.07; 3.73)
Year 2 / 2 / 6,812 / <0.1 (0.0; 0.1) / 6 / 3,407 / 0.2 (0.1; 0.4) / 0.167 / (0.02; 0.93)
Years 1 & 2 / 5 / 6,830 / <0.1 (0.0; 0.1) / 9 / 3,416 / 0.1 (0.1; 0.2) / 0.278 / (0.07; 0.92)
Year 3 / 2 / 6,778 / <0.1 (0.0; 0.1) / 0 / 3,387 / 0.0 (0.0; 0.1) / NC / (NC)
Year 4 / 3 / 6,755 / <0.1 (0.0; 0.1) / 1 / 3,376 / <0.1 (0.0; 0.2) / 1.499 / (0.12; 78.71)
Years 3 & 4 / 5 / 6,767 / <0.1 (0.0; 0.1) / 1 / 3,382 / <0.1 (0.0; 0.1) / 2.499 / (0.28; 118.18)
Years 1 to 4 / 10 / 6,798 / <0.1 (0.0; 0.1) / 10 / 3,399 / <0.1 (0.0; 0.1) / 0.500 / (0.19; 1.34)
Serotype 2 / Year 1 / 1 / 6,848 / <0.1 (0.0; 0.1) / 2 / 3,424 / <0.1 (0.0; 0.2) / 0.250 / (0.00; 4.80)
Year 2 / 2 / 6,812 / <0.1 (0.0; 0.1) / 3 / 3,407 / <0.1 (0.0; 0.2) / 0.333 / (0.03; 2.91)
Years 1 & 2 / 3 / 6,830 / <0.1 (0.0; 0.1) / 5 / 3,416 / <0.1 (0.0; 0.2) / 0.300 / (0.05; 1.54)
Year 3 / 2 / 6,778 / <0.1 (0.0; 0.1) / 0 / 3,387 / 0.0 (0.0; 0.1) / NC / (NC)
Year 4 / 7 / 6,755 / 0.1 (0.0; 0.2) / 4 / 3,376 / 0.1 (0.0; 0.3) / 0.875 / (0.22; 4.07)
Years 3 & 4 / 9 / 6,767 / <0.1 (0.0; 0.1) / 4 / 3,382 / <0.1 (0.0; 0.2) / 1.124 / (0.31; 5.00)
Years 1 to 4 / 12 / 6,798 / <0.1 (0.0; 0.1) / 9 / 3,399 / <0.1 (0.0; 0.1) / 0.667 / (0.26; 1.79)
Serotype 3 / Year 1 / 2 / 6,848 / <0.1 (0.0; 0.1) / 1 / 3,424 / <0.1 (0.0; 0.2) / 1.000 / (0.05; 59.00)
Year 2 / 0 / 6,812 / 0.0 (0.0; 0.0) / 2 / 3,407 / <0.1 (0.0; 0.2) / 0.000 / (0.00; 2.66)
Years 1 & 2 / 2 / 6,830 / <0.1 (0.0; 0.1) / 3 / 3,416 / <0.1 (0.0; 0.1) / 0.333 / (0.03; 2.91)
Year 3 / 7 / 6,778 / 0.1 (0.0; 0.2) / 0 / 3,387 / 0.0 (0.0; 0.1) / NC / (NC)
Year 4 / 3 / 6,755 / <0.1 (0.0; 0.1) / 1 / 3,376 / <0.1 (0.0; 0.2) / 1.499 / (0.12; 78.71)
Years 3 & 4 / 10 / 6,767 / <0.1 (0.0; 0.1) / 1 / 3,382 / <0.1 (0.0; 0.1) / 4.997 / (0.71; 216.88)
Years 1 to 4 / 12 / 6,798 / <0.1 (0.0; 0.1) / 4 / 3,399 / <0.1 (0.0; 0.1) / 1.500 / (0.45; 6.38)
Serotype 4 / Year 1 / 1 / 6,848 / <0.1 (0.0; 0.1) / 1 / 3,424 / <0.1 (0.0; 0.2) / 0.500 / (0.01; 39.25)
Year 2 / 1 / 6,812 / <0.1 (0.0; 0.1) / 3 / 3,407 / <0.1 (0.0; 0.2) / 0.167 / (0.00; 2.08)
Years 1 & 2 / 2 / 6,830 / <0.1 (0.0; 0.1) / 4 / 3,416 / <0.1 (0.0; 0.1) / 0.250 / (0.02; 1.74)
Year 3 / 0 / 6,778 / 0.0 (0.0; 0.1) / 1 / 3,387 / <0.1 (0.0; 0.2) / 0.000 / (0.00; 19.49)
Year 4 / 0 / 6,755 / 0.0 (0.0; 0.1) / 0 / 3,376 / 0.0 (0.0; 0.1) / NC / (NC)
Years 3 & 4 / 0 / 6,767 / 0.0 (0.0; 0.0) / 1 / 3,382 / <0.1 (0.0; 0.1) / 0.000 / (0.00; 19.49)
Years 1 to 4 / 2 / 6,798 / <0.1 (0.0; 0.0) / 5 / 3,399 / <0.1 (0.0; 0.1) / 0.200 / (0.02; 1.22)
CYD23/57
Any serotypes / Year 1 / 1 / 2,666 / <0.1 (0.0; 0.2) / 0 / 1,331 / 0.0 (0.0; 0.3) / NC / (NC)
Year 2 / 1 / 2,576 / <0.1 (0.0; 0.2) / 2 / 1,292 / 0.1 (0.0; 0.5) / 0.251 / (0.00; 4.82)
Years 1 & 2 / 2 / 2,621 / <0.1 (0.0; 0.1) / 2 / 1,312 / <0.1 (0.0; 0.3) / 0.500 / (0.04; 6.90)
Year 3 / 4 / 2,131 / 0.2 (0.1; 0.5) / 0 / 1,072 / 0.0 (0.0; 0.4) / NC / (NC)
Year 4 / 1 / 2,131 / <0.1 (0.0; 0.3) / 2 / 1,072 / 0.2 (0.0; 0.7) / 0.252 / (0.00; 4.83)
Years 3 & 4 / 5 / 2,131 / 0.1 (0.0; 0.3) / 2 / 1,072 / <0.1 (0.0; 0.4) / 1.258 / (0.21; 13.21)
Years 1 to 4 / 7 / 2,376 / <0.1 (0.0; 0.2) / 4 / 1,192 / <0.1 (0.0; 0.2) / 0.878 / (0.22; 4.09)
Serotype 1 / Year 1 / 0 / 2,666 / 0.0 (0.0; 0.1) / 0 / 1,331 / 0.0 (0.0; 0.3) / NC / (NC)
Year 2 / 1 / 2,576 / <0.1 (0.0; 0.2) / 1 / 1,292 / <0.1 (0.0; 0.4) / 0.502 / (0.01; 39.37)
Years 1 & 2 / 1 / 2,621 / <0.1 (0.0; 0.1) / 1 / 1,312 / <0.1 (0.0; 0.2) / 0.500 / (0.01; 39.28)
Year 3 / 4 / 2,131 / 0.2 (0.1; 0.5) / 0 / 1,072 / 0.0 (0.0; 0.4) / NC / (NC)
Year 4 / 1 / 2,131 / <0.1 (0.0; 0.3) / 0 / 1,072 / 0.0 (0.0; 0.3) / NC / (NC)
Years 3 & 4 / 5 / 2,131 / 0.1 (0.0; 0.3) / 0 / 1,072 / 0.0 (0.0; 0.2) / NC / (NC)
Years 1 to 4 / 6 / 2,376 / <0.1 (0.0; 0.1) / 1 / 1,192 / <0.1 (0.0; 0.1) / 3.009 / (0.37; 138.43)
Serotype 2 / Year 1 / 1 / 2,666 / <0.1 (0.0; 0.2) / 0 / 1,331 / 0.0 (0.0; 0.3) / NC / (NC)
Year 2 / 0 / 2,576 / 0.0 (0.0; 0.1) / 1 / 1,292 / <0.1 (0.0; 0.4) / 0.000 / (0.00; 19.56)
Years 1 & 2 / 1 / 2,621 / <0.1 (0.0; 0.1) / 1 / 1,312 / <0.1 (0.0; 0.2) / 0.500 / (0.01; 39.28)
Year 3 / 1 / 2,131 / <0.1 (0.0; 0.3) / 0 / 1,072 / 0.0 (0.0; 0.4) / NC / (NC)
Year 4 / 0 / 2,131 / 0.0 (0.0; 0.2) / 1 / 1,072 / <0.1 (0.0; 0.5) / 0.000 / (0.00; 19.62)
Years 3 & 4 / 1 / 2,131 / <0.1 (0.0; 0.1) / 1 / 1,072 / <0.1 (0.0; 0.3) / 0.503 / (0.01; 39.49)
Years 1 to 4 / 2 / 2,376 / <0.1 (0.0; 0.1) / 2 / 1,192 / <0.1 (0.0; 0.2) / 0.502 / (0.04; 6.92)
Serotype 3 / Year 1 / 0 / 2,666 / 0.0 (0.0; 0.1) / 0 / 1,331 / 0.0 (0.0; 0.3) / NC / (NC)
Year 2 / 0 / 2,576 / 0.0 (0.0; 0.1) / 0 / 1,292 / 0.0 (0.0; 0.3) / NC / (NC)
Years 1 & 2 / 0 / 2,621 / 0.0 (0.0; 0.1) / 0 / 1,312 / 0.0 (0.0; 0.1) / NC / (NC)
Year 3 / 0 / 2,131 / 0.0 (0.0; 0.2) / 0 / 1,072 / 0.0 (0.0; 0.4) / NC / (NC)
Year 4 / 0 / 2,131 / 0.0 (0.0; 0.2) / 0 / 1,072 / 0.0 (0.0; 0.3) / NC / (NC)
Years 3 & 4 / 0 / 2,131 / 0.0 (0.0; 0.1) / 0 / 1,072 / 0.0 (0.0; 0.2) / NC / (NC)
Years 1 to 4 / 0 / 2,376 / 0.0 (0.0; 0.0) / 0 / 1,192 / 0.0 (0.0; 0.1) / NC / (NC)
Serotype 4 / Year 1 / 0 / 2,666 / 0.0 (0.0; 0.1) / 0 / 1,331 / 0.0 (0.0; 0.3) / NC / (NC)
Year 2 / 0 / 2,576 / 0.0 (0.0; 0.1) / 0 / 1,292 / 0.0 (0.0; 0.3) / NC / (NC)
Years 1 & 2 / 0 / 2,621 / 0.0 (0.0; 0.1) / 0 / 1,312 / 0.0 (0.0; 0.1) / NC / (NC)
Year 3 / 0 / 2,131 / 0.0 (0.0; 0.2) / 0 / 1,072 / 0.0 (0.0; 0.4) / NC / (NC)
Year 4 / 0 / 2,131 / 0.0 (0.0; 0.2) / 1 / 1,072 / <0.1 (0.0; 0.5) / 0.000 / (0.00; 19.62)
Years 3 & 4 / 0 / 2,131 / 0.0 (0.0; 0.1) / 1 / 1,072 / <0.1 (0.0; 0.3) / 0.000 / (0.00; 19.62)
Years 1 to 4 / 0 / 2,376 / 0.0 (0.0; 0.0) / 1 / 1,192 / <0.1 (0.0; 0.1) / 0.000 / (0.00; 19.56)
CYD15
Any serotypes / Year 1 / 0 / 13,915 / 0.0 (0.0; 0.0) / 5 / 6,939 / <0.1 (0.0; 0.2) / 0.000 / (0.00; 0.54)
Year 2 / 0 / 13,522 / 0.0 (0.0; 0.0) / 6 / 6,749 / <0.1 (0.0; 0.2) / 0.000 / (0.00; 0.42)
Years 1 & 2 / 0 / 13,719 / 0.0 (0.0; 0.0) / 11 / 6,844 / <0.1 (0.0; 0.1) / 0.000 / (0.00; 0.20)
Year 3 / 3 / 13,268 / <0.1 (0.0; 0.1) / 5 / 6,630 / <0.1 (0.0; 0.2) / 0.300 / (0.05; 1.54)
Year 4 / 2 / 13,009 / <0.1 (0.0; 0.1) / 0 / 6,524 / 0.0 (0.0; 0.1) / NC / (NC)
Years 3 & 4 / 5 / 13,139 / <0.1 (0.0; 0.0) / 5 / 6,577 / <0.1 (0.0; 0.1) / 0.501 / (0.12; 2.18)
Years 1 to 4 / 5 / 13,429 / <0.1 (0.0; 0.0) / 16 / 6,711 / <0.1 (0.0; 0.1) / 0.156 / (0.04; 0.45)
Serotype 1 / Year 1 / 0 / 13,915 / 0.0 (0.0; 0.0) / 3 / 6,939 / <0.1 (0.0; 0.1) / 0.000 / (0.00; 1.21)
Year 2 / 0 / 13,522 / 0.0 (0.0; 0.0) / 0 / 6,749 / 0.0 (0.0; 0.1) / NC / (NC)
Years 1 & 2 / 0 / 13,719 / 0.0 (0.0; 0.0) / 3 / 6,844 / <0.1 (0.0; 0.1) / 0.000 / (0.00; 1.21)
Year 3 / 2 / 13,268 / <0.1 (0.0; 0.1) / 1 / 6,630 / <0.1 (0.0; 0.1) / 0.999 / (0.05; 58.96)
Year 4 / 1 / 13,009 / <0.1 (0.0; 0.0) / 0 / 6,524 / 0.0 (0.0; 0.1) / NC / (NC)
Years 3 & 4 / 3 / 13,139 / <0.1 (0.0; 0.0) / 1 / 6,577 / <0.1 (0.0; 0.0) / 1.502 / (0.12; 78.84)
Years 1 to 4 / 3 / 13,429 / <0.1 (0.0; 0.0) / 4 / 6,711 / <0.1 (0.0; 0.0) / 0.375 / (0.05; 2.22)
Serotype 2 / Year 1 / 0 / 13,915 / 0.0 (0.0; 0.0) / 1 / 6,939 / <0.1 (0.0; 0.1) / 0.000 / (0.00; 19.45)
Year 2 / 0 / 13,522 / 0.0 (0.0; 0.0) / 3 / 6,749 / <0.1 (0.0; 0.1) / 0.000 / (0.00; 1.21)
Years 1 & 2 / 0 / 13,719 / 0.0 (0.0; 0.0) / 4 / 6,844 / <0.1 (0.0; 0.1) / 0.000 / (0.00; 0.76)
Year 3 / 1 / 13,268 / <0.1 (0.0; 0.0) / 4 / 6,630 / <0.1 (0.0; 0.2) / 0.125 / (0.00; 1.26)
Year 4 / 1 / 13,009 / <0.1 (0.0; 0.0) / 0 / 6,524 / 0.0 (0.0; 0.1) / NC / (NC)
Years 3 & 4 / 2 / 13,139 / <0.1 (0.0; 0.0) / 4 / 6,577 / <0.1 (0.0; 0.1) / 0.250 / (0.02; 1.75)
Years 1 to 4 / 2 / 13,429 / <0.1 (0.0; 0.0) / 8 / 6,711 / <0.1 (0.0; 0.1) / 0.125 / (0.01; 0.63)
Serotype 3 / Year 1 / 0 / 13,915 / 0.0 (0.0; 0.0) / 1 / 6,939 / <0.1 (0.0; 0.1) / 0.000 / (0.00; 19.45)
Year 2 / 0 / 13,522 / 0.0 (0.0; 0.0) / 2 / 6,749 / <0.1 (0.0; 0.1) / 0.000 / (0.00; 2.66)
Years 1 & 2 / 0 / 13,719 / 0.0 (0.0; 0.0) / 3 / 6,844 / <0.1 (0.0; 0.1) / 0.000 / (0.00; 1.21)
Year 3 / 0 / 13,268 / 0.0 (0.0; 0.0) / 0 / 6,630 / 0.0 (0.0; 0.1) / NC / (NC)
Year 4 / 0 / 13,009 / 0.0 (0.0; 0.0) / 0 / 6,524 / 0.0 (0.0; 0.1) / NC / (NC)
Years 3 & 4 / 0 / 13,139 / 0.0 (0.0; 0.0) / 0 / 6,577 / 0.0 (0.0; 0.0) / NC / (NC)
Years 1 to 4 / 0 / 13,429 / 0.0 (0.0; 0.0) / 3 / 6,711 / <0.1 (0.0; 0.0) / 0.000 / (0.00; 1.21)
Serotype 4 / Year 1 / 0 / 13,915 / 0.0 (0.0; 0.0) / 0 / 6,939 / 0.0 (0.0; 0.1) / NC / (NC)
Year 2 / 0 / 13,522 / 0.0 (0.0; 0.0) / 1 / 6,749 / <0.1 (0.0; 0.1) / 0.000 / (0.00; 19.47)
Years 1 & 2 / 0 / 13,719 / 0.0 (0.0; 0.0) / 1 / 6,844 / <0.1 (0.0; 0.0) / 0.000 / (0.00; 19.46)
Year 3 / 0 / 13,268 / 0.0 (0.0; 0.0) / 0 / 6,630 / 0.0 (0.0; 0.1) / NC / (NC)
Year 4 / 0 / 13,009 / 0.0 (0.0; 0.0) / 0 / 6,524 / 0.0 (0.0; 0.1) / NC / (NC)
Years 3 & 4 / 0 / 13,139 / 0.0 (0.0; 0.0) / 0 / 6,577 / 0.0 (0.0; 0.0) / NC / (NC)
Years 1 to 4 / 0 / 13,429 / 0.0 (0.0; 0.0) / 1 / 6,711 / <0.1 (0.0; 0.0) / 0.000 / (0.00; 19.49)
CYD14 + CYD23/57 + CYD15
Any serotypes / Year 1 / 8 / 23,429 / <0.1 (0.0; 0.1) / 12 / 11,694 / 0.1 (0.1; 0.2) / 0.333 / (0.12; 0.89)
Year 2 / 6 / 22,910 / <0.1 (0.0; 0.1) / 21 / 11,448 / 0.2 (0.1; 0.3) / 0.143 / (0.05; 0.37)
Years 1 & 2 / 14 / 23,170 / <0.1 (0.0; 0.0) / 33 / 11,571 / 0.1 (0.1; 0.2) / 0.212 / (0.10; 0.41)
Year 3 / 18 / 22,177 / <0.1 (0.1; 0.1) / 6 / 11,089 / <0.1 (0.0; 0.1) / 1.500 / (0.57; 4.62)
Year 4 / 16 / 21,895 / <0.1 (0.0; 0.1) / 8 / 10,972 / <0.1 (0.0; 0.1) / 1.002 / (0.40; 2.70)
Years 3 & 4 / 34 / 22,036 / <0.1 (0.1; 0.1) / 14 / 11,031 / <0.1 (0.0; 0.1) / 1.216 / (0.64; 2.45)
Years 1 to 4 / 48 / 22,603 / <0.1 (0.0; 0.1) / 47 / 11,301 / 0.1 (0.1; 0.1) / 0.511 / (0.33; 0.78)
Serotype 1 / Year 1 / 3 / 23,429 / <0.1 (0.0; 0.0) / 6 / 11,694 / <0.1 (0.0; 0.1) / 0.250 / (0.04; 1.17)
Year 2 / 3 / 22,910 / <0.1 (0.0; 0.0) / 7 / 11,448 / <0.1 (0.0; 0.1) / 0.214 / (0.04; 0.94)
Years 1 & 2 / 6 / 23,170 / <0.1 (0.0; 0.0) / 13 / 11,571 / <0.1 (0.0; 0.1) / 0.230 / (0.07; 0.65)
Year 3 / 8 / 22,177 / <0.1 (0.0; 0.1) / 1 / 11,089 / <0.1 (0.0; 0.1) / 4.000 / (0.54; 177.50)
Year 4 / 5 / 21,895 / <0.1 (0.0; 0.1) / 1 / 10,972 / <0.1 (0.0; 0.1) / 2.506 / (0.28; 118.51)
Years 3 & 4 / 13 / 22,036 / <0.1 (0.0; 0.1) / 2 / 11,031 / <0.1 (0.0; 0.0) / 3.254 / (0.74; 29.70)
Years 1 to 4 / 19 / 22,603 / <0.1 (0.0; 0.0) / 15 / 11,301 / <0.1 (0.0; 0.1) / 0.633 / (0.30; 1.34)
Serotype 2 / Year 1 / 2 / 23,429 / <0.1 (0.0; 0.0) / 3 / 11,694 / <0.1 (0.0; 0.1) / 0.333 / (0.03; 2.90)
Year 2 / 2 / 22,910 / <0.1 (0.0; 0.0) / 7 / 11,448 / <0.1 (0.0; 0.1) / 0.143 / (0.01; 0.75)
Years 1 & 2 / 4 / 23,170 / <0.1 (0.0; 0.0) / 10 / 11,571 / <0.1 (0.0; 0.1) / 0.200 / (0.05; 0.69)
Year 3 / 4 / 22,177 / <0.1 (0.0; 0.1) / 4 / 11,089 / <0.1 (0.0; 0.1) / 0.500 / (0.09; 2.68)
Year 4 / 8 / 21,895 / <0.1 (0.0; 0.1) / 5 / 10,972 / <0.1 (0.0; 0.1) / 0.802 / (0.23; 3.11)
Years 3 & 4 / 12 / 22,036 / <0.1 (0.0; 0.0) / 9 / 11,031 / <0.1 (0.0; 0.1) / 0.667 / (0.26; 1.79)
Years 1 to 4 / 16 / 22,603 / <0.1 (0.0; 0.0) / 19 / 11,301 / <0.1 (0.0; 0.1) / 0.421 / (0.20; 0.86)
Serotype 3 / Year 1 / 2 / 23,429 / <0.1 (0.0; 0.0) / 2 / 11,694 / <0.1 (0.0; 0.1) / 0.499 / (0.04; 6.89)
Year 2 / 0 / 22,910 / 0.0 (0.0; 0.0) / 4 / 11,448 / <0.1 (0.0; 0.1) / 0.000 / (0.00; 0.76)
Years 1 & 2 / 2 / 23,170 / <0.1 (0.0; 0.0) / 6 / 11,571 / <0.1 (0.0; 0.1) / 0.166 / (0.02; 0.93)
Year 3 / 7 / 22,177 / <0.1 (0.0; 0.1) / 0 / 11,089 / 0.0 (0.0; 0.0) / NC / (NC)
Year 4 / 3 / 21,895 / <0.1 (0.0; 0.0) / 1 / 10,972 / <0.1 (0.0; 0.1) / 1.503 / (0.12; 78.92)
Years 3 & 4 / 10 / 22,036 / <0.1 (0.0; 0.0) / 1 / 11,031 / <0.1 (0.0; 0.0) / 5.006 / (0.71; 217.23)
Years 1 to 4 / 12 / 22,603 / <0.1 (0.0; 0.0) / 7 / 11,301 / <0.1 (0.0; 0.0) / 0.857 / (0.31; 2.57)
Serotype 4 / Year 1 / 1 / 23,429 / <0.1 (0.0; 0.0) / 1 / 11,694 / <0.1 (0.0; 0.0) / 0.499 / (0.01; 39.18)
Year 2 / 1 / 22,910 / <0.1 (0.0; 0.0) / 4 / 11,448 / <0.1 (0.0; 0.1) / 0.125 / (0.00; 1.26)
Years 1 & 2 / 2 / 23,170 / <0.1 (0.0; 0.0) / 5 / 11,571 / <0.1 (0.0; 0.0) / 0.200 / (0.02; 1.22)
Year 3 / 0 / 22,177 / 0.0 (0.0; 0.0) / 1 / 11,089 / <0.1 (0.0; 0.1) / 0.000 / (0.00; 19.50)
Year 4 / 0 / 21,895 / 0.0 (0.0; 0.0) / 1 / 10,972 / <0.1 (0.0; 0.1) / 0.000 / (0.00; 19.54)
Years 3 & 4 / 0 / 22,036 / 0.0 (0.0; 0.0) / 2 / 11,031 / <0.1 (0.0; 0.0) / 0.000 / (0.00; 2.67)
Years 1 to 4 / 2 / 22,603 / <0.1 (0.0; 0.0) / 7 / 11,301 / <0.1 (0.0; 0.0) / 0.143 / (0.01; 0.75)
M: number of participants present at the beginning of each year or mean of number of subjects followed during the years included in the considered period; Cases: number of participants with at least one hospitalisation for virologically-confirmed dengue episode meeting the Independent Data Monitoring Committee criteria with the given serotype detected; NC: Not calculated; The annual incidence rate: cases among M * 100 converted into the annual rate.1Severity was assessed using the Independent Data Monitoring Committee (IDMC) criteria.
Two VCD cases, judged to be clinically-severe, were not hospitalised: one in the CYD14 control group and one in the CYD15 CYD-TDV group, were not included in the analysis.